Naptumomab Estafenatox (TPBG) - Research Grade Biosimilar

• Background:

  Naptumomab Estafenatox has been used in trials studying the treatment of Pancreatic Cancer, Renal Cell Carcinoma, and Non-Small-Cell Lung Carcinoma.

• Immunogen:

  Mus musculus / TPBG [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  Fab-G1-kappa

• Specificity:

  Please note: 10-087 is the pure recombinant antibody Naptumomab without Estafenatox fragment. The original antibody drug is the fusion protein «Naptumomab + Estafenatox», however, the research grade biosimilar we can supply is the recombinant antibody without any conjugation or any fragment.

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  ABR-217620, ANYARA, TTS CD3, TPBG, TPBG